Tirallero 60 mg (Ticagrelor)

Adult dose

This medicine should not be used concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment for 12 months is recommended unless discontinuation is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who have an increased risk of bleeding after undergoing percutaneous coronary intervention (PCI), monotherapy with this medicine (discontinuing aspirin) may be considered after 3 months of concomitant treatment with this medicine and aspirin. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who took 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the corresponding dosage and administration instructions. Data on the safety and efficacy of this medicine when administered for more than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a cup of water, and drink it immediately; then rinse the cup with another half cup of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. If switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and there is limited experience with its use in patients with moderate hepatic impairment.

Child dose

The safety and efficacy have not been established in pediatric patients under 18 years of age.

This medication prevents platelet aggregation in the blood to prevent clot formation. It should not be used in patients with active bleeding or a history of intracranial hemorrhage, as it may increase the risk of bleeding. If surgery is planned, this medication should be discontinued at least 5 days prior, and immediate medical attention should be sought if bleeding symptoms occur. Patients with a high risk of bleeding or severely impaired liver function should use this medication cautiously, and caution is required when combined with other bleeding risk medications. During treatment with this medication, symptoms such as shortness of breath, bradycardia (slow heart rate), or bleeding may occur, and any unusual symptoms should be reported to healthcare professionals immediately. Pregnant or breastfeeding women should consult a physician before taking this medication, as it may affect the fetus or newborn. This medication is not recommended for children under 18 years of age, as its safety and efficacy have not been established. In cases of overdose, the risk of bleeding may increase; therefore, it is important to avoid exceeding the recommended dose, and if an overdose occurs, immediate medical attention should be sought. This medication may interact with other drugs, so patients should inform their doctor or pharmacist of any other medications they are taking. Dizziness or confusion may occur during treatment, so special care should be taken when driving or operating machinery. This medication should be stored out of the reach of children and preferably kept in its original container.

Hemorrhage, dyspnea, hyperuricemia, gout, confusion, dizziness, syncope, headache, intracranial hemorrhage, ocular hemorrhage, vertigo, ear hemorrhage, hypotension, respiratory tract hemorrhage, gastrointestinal hemorrhage, diarrhea, nausea, dyspepsia, constipation, retroperitoneal hemorrhage, subcutaneous or skin hemorrhage, rash, pruritus, muscle hemorrhage, urinary tract hemorrhage, genital hemorrhage, elevated serum creatinine, post-procedural hemorrhage, traumatic hemorrhage, thrombotic thrombocytopenic purpura, bradyarrhythmia, atrioventricular block, angioedema, central sleep apnea including Cheyne-Stokes respiration, chest pain, cough, pulmonary hemorrhage, pharyngitis, upper respiratory infection, asthma, pleural effusion, bronchitis, pneumothorax, pneumonia, pulmonary edema, weakness, anaphylactic shock, epistaxis, hemoptysis, hematoma, cerebral hemorrhage, spinal canal stenosis, dementia, migraine, paralysis, gait abnormality, rectal hemorrhage, anal hemorrhage, appendicitis, connective tissue disease, bursitis, rhabdomyolysis, acute renal failure, heart failure, palpitations, ventricular tachycardia, arrhythmia, ventricular fibrillation, cardiac arrest, atrial fibrillation, atrial arrhythmia, complete heart block, urinary tract infection, nephrolithiasis, cerebral ischemia, venous stenosis, cerebral infarction, arterial stenosis, angina pectoris, coronary thrombosis, myocardial ischemia, aneurysm, cardiac rhythm disorder, anemia, vestibular disorder, malignant male genital neoplasm, chemical poisoning, post-procedural hematoma, laceration, road traffic accident, trauma, nausea, vomiting, chest pain, back pain, myalgia, skeletal pain, arthralgia, urticaria, increased sweating, hypokalemia, diabetes mellitus, hypocalcemia, hyperkalemia, hyperglycemia, thirst, hypomagnesemia, hypoglycemia, increased AST, increased ALT, insomnia, anxiety, memory impairment, erectile dysfunction, agitation, orthostatic hypotension, palpitations, bradycardia, conjunctival injection, eye pain, visual disturbances, frequent urination, dysuria, urinary incontinence, nocturia, worsening of chronic renal failure, cystitis, abnormal urination, renal cysts, urinary retention, azotemia, cyanosis, visual disturbances, tinnitus, ear pain, lymphadenopathy, eosinophilia, sexual dysfunction, benign prostatic hyperplasia, ovarian cysts, amenorrhea, vaginitis, loss of taste, olfactory disturbance, increased TSH, hypothyroidism, injection site reactions, pain at the injection site

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to store it at room temperature between 1°C and 30°C.

Appearance

Pink, bilayered, biconvex, film-coated tablet

Package unit

30 tablets - 30 tablets/PTP [(10 tablets/PTPx3)]